Pfizer-Drug Xalkori Approved for Lung Cancer, but at What Cost?
By IBTimes Staff Reporter | August 31, 2011 5:54 AM EST
Xalkori is used to treat certain patients with late-stage -- advanced or metastatic -- lung cancer along with an abnormal anaplastic lymphoma kinase (ALK) gene, which causes cancer development and growth.
The drug, which works by blocking certain proteins called kinases, including the protein produced by gene abnormality, is being approved with a companion diagnostic test from Abbott Molecular Oncology that helped determine if a patient has the gene.
“The approval of Xalkori with a specific test allows the selection of patients who are more likely to respond to the drug,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA’s Center for Drug Evaluation and Research. “Targeted therapies such as Xalkori are important options for treating patients with this disease and may ultimately result in fewer side effects.”
The Wall Street Journal reports that, four years ago, Pfizer Inc. was on the verge of abandoning a cancer therapy until scientists discovered its effectiveness for, at the time, only a small group of people -- 6,000 patients a year in the U.S.
"The results may not achieve multi-billion-dollar sales, but whether that yields a product for tens of millions of patients or 10,000 patients, we're interested," Geno Germano, who runs Pfizer's specialty-care and cancer businesses, told WSJ.
In two clinical trials involving about 255 patients, Xalkori delayed tumor progression for at least ten months in slightly more than half the patients who had a specific genetic mutation, the study noted.
Roughly one to seven percent of those with larger-celled lung cancer have the ALK gene abnormality, according to the FDA. Patients with this form of lung cancer are typically non-smokers.
Federal health regulators discussed the drug shortly after its U.S. approval based on it being "reasonably likely to predict a clinical benefit to [lung cancer] patients," they said.
Xalkori is approved for the roughly four percent of patients with non-small cell lung cancer who have the gene.
In one study, the objective response rate was 50 percent with a median response duration of 42 weeks. In another, the objective response rate was 61 percent with a median response duration of 48 weeks with most patients tested had tumors shrink or disappear for months, without the nasty side effects of chemotherapy..
FDA officials said the most common side effects reported in patients receiving Xalkori included vision disorders, nausea, diarrhea, vomiting, swelling, and constipation.
Pfizer plans to charge $115,200 a year per patient for Xalkori.
To contact the editor, e-mail:
Most Popular Slideshows
- Still The World Champions: Team USA Overpowers Serbia, 129-92 To Win 2014 FIBA World Cup [PHOTOS]
- Pope Francis: World War III Has Started On Piecemeal
- After Win Over Maidana, Mayweather Says He Is Prepared To Negotiate A Fight With Pacquiao
- From Fat To Fit: Celebrities Who Were Overweight Before They Became The Beauties That They Are
Join the Conversation
- Maria Menounos Lost 40 Pounds; She Follows a Low Carb Vegetarian Diet, Her Weight Loss and Fitness Secrets Revealed
- 'Django Unchained' Actress Danielle Watts Mistaken As Prostitute And Arrested; Accused Police of Racism
- Airborne Version of Ebola Virus Could Wipe Out 1.2 Million; Aussie Doctor Appeals For Help
- A Wife's Happiness is More Crucial Than Her Husband's For a Long Lasting, Happy Marriage, Finds Study
- Kim Kardashian's Pregnancy Glow Returns; Rumour Mill Suggests That Kim Is Pregnant
- Google Release Roundup: Nexus 5 2014, Nexus 6, Nexus 8 and Android L Killer Features
- Samsung Attacks iPhone 6 Plus Through New Galaxy Note 4 Commercial: Apple Claims Imitating Galaxy Note Phablets
- iPhone 6 And IPhone 6 Plus Sold Out, New Stocks To Arrive In October
- Pregnant Kate Middleton May Call Off Malta Trip Due To Sickness: Royal Couple Will Move To Anmer Hall Residence
- Moto G (Gen 2) vs. Xiaomi Redmi 1S—Specifications, Features And Price Showdown
- Nexus 6, 8 Release Dates Imminent as Moto X Pre-Order Begins & Nexus 7 Deals Ramp Up
- iPhone 6 And iPhone 6 Plus Shipping Has Begun, Expected To Reach Customers’ Doorstep On Sept 19 Launch Date